BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 33586097)

  • 1. Correlations between whole body volumetric parameters of
    Yildirim ÖA; Gündoğan C; Can C; Poyraz K; Erdur E; Kömek H
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
    Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
    Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of (
    Yilmaz U; Komek H; Can C; Altindag S
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of
    Can C; Gündoğan C; Yildirim OA; Poyraz K; Güzel Y; Kömek H
    Hell J Nucl Med; 2021; 24(1):25-35. PubMed ID: 33866336
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,
    Akkaya H; Dilek O; Özdemir S; Taş ZA; Öztürk İS; Gülek B
    Diagn Interv Radiol; 2023 Sep; 29(5):647-655. PubMed ID: 37395389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
    Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
    Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of
    Chen R; Wang Y; Shi Y; Zhu Y; Xu L; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2970-2977. PubMed ID: 33528607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Schmidkonz C; Cordes M; Schmidt D; Bäuerle T; Goetz TI; Beck M; Prante O; Cavallaro A; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
    Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1862-1872. PubMed ID: 29725716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlations of
    Topuz ÖV; Aksu A; Erinç SR; Tamam MÖ
    Hell J Nucl Med; 2021; 24(1):60-65. PubMed ID: 33866340
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Added Value of
    Chen R; Wang Y; Zhu Y; Shi Y; Xu L; Huang G; Liu J
    J Nucl Med; 2022 Jan; 63(1):69-75. PubMed ID: 34980667
    [No Abstract]   [Full Text] [Related]  

  • 16. PSA-stratified detection rates for [
    Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Akdemir EN; Tuncel M; Akyol F; Bilen CY; Baydar DE; Karabulut E; Ozen H; Caglar M
    World J Urol; 2019 May; 37(5):813-821. PubMed ID: 30151600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
    Özülker T; Özülker F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The management impact of
    Kulkarni M; Hughes S; Mallia A; Gibson V; Young J; Aggarwal A; Morris S; Challacombe B; Popert R; Brown C; Cathcart P; Dasgupta P; Warbey VS; Cook GJR
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):674-686. PubMed ID: 31872280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of quantitative whole body PET parameters on [
    Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
    Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.